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Abstract
BACKGROUND—Recombinant interleukin-2 (rIL-2) induces cellular cytotoxicity against
leukemia blasts. Patients with acute myeloid leukemia (AML) in first complete remission (CR)
may harbor minimal residual disease that is susceptible to rIL-2–activated effector cells.
METHODS—In the Cancer and Leukemia Group B (CALGB) 19808 study, patients with AML
in first CR were randomly assigned after all planned chemotherapy to receive a 90-day course of
subcutaneously administered rIL-2 or no further therapy. The primary objective was to compare
disease-free survival (DFS) between the 2 treatment arms. A total of 534 patients achieved a CR,
214 of whom were randomized. Six courses of low-dose daily rIL-2 were given for the expansion
of cytotoxic effector cells, each followed by 3-day high-dose boluses given to trigger cytotoxicity
against minimal residual disease.
RESULTS—On the protocol-specified intention-to-treat analysis, the hazards ratio for DFS was
0.75 (95% confidence interval, 0.52–1.09; P =.13); the 5-year DFS rate was 42% in the
observation arm and 53% in the rIL-2 treatment arm. The hazards ratio for overall survival (OS)
was 0.88 (95% confidence interval, 0.54–1.23; P =.34); the 5-year OS rate was 58% for the
observation arm and 63% for the rIL-2 treatment arm. Twenty-five of the 107 patients randomized
to treatment with rIL-2 either refused or were unable to initiate therapy and 30 patients did not
complete their assigned therapy. However, significant toxicities were not commonly observed.
The trial design did not anticipate the difficulties patients would encounter with protocol
compliance.
CONCLUSIONS—The efficacy of immunotherapy with rIL-2 administered after intensive
postremission treatment was not assessed as planned because of unexpected refusals by patients
and/or their physicians to comply with protocol-directed therapy. Neither DFS nor OS was found
to be significantly improved.
Keywords
acute myeloid leukemia; recombinant interleukin-2; phase 3; immunotherapy; adjuvant therapy
INTRODUCTION
Recombinant interleukin-2 (rIL-2) induces cytotoxicity against tumor targets mediated by
cytotoxic T cells and natural killer (NK) cells.1,2 Responses have been described in patients
with recurrent and refractory acute myeloid leukemia (AML).3,4 Prior studies of rIL-2
treatment alone in patients with AML in first complete remission (CR) have not
demonstrated improvements in outcomes.5
Beginning in 1994, the Cancer and Leukemia Group B (CALGB) initiated a series of trials
in patients with AML in first CR6–8 using doses and schedules of rIL-2 that induce the
expansion and cytotoxicity of NK cells with acceptable toxicity.9 We hypothesized that
immunotherapy would be most effective when administered at the time of minimal residual
disease. We now report outcomes from a randomization between rIL-2 and observation for
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patients in CR after the completion of all planned postremission therapy on the CALGB
(Alliance) 19808 trial. Patients were randomized after receiving either high-dose cytarabine
(HiDAC) consolidation or autologous hematopoietic stem cell transplantation (AHSCT),
depending on cytogenetic risk. The feasibility and safety of treatment with rIL-2 after
AHSCT has been previously shown.10,11 The goal was to assess the impact of rIL-2
immunotherapy on disease-free survival (DFS).
MATERIALS AND METHODS
Previously untreated patients aged <60 years with AML in first CR were randomized
between 2 treatment arms: rIL-2 and observation. Patients with acute promyelocytic
leukemia, therapy-related AML, or AML arising from a prior myeloproliferative disorder or
those with a history of bone marrow-proven myelodysplastic syndrome of >3 months were
excluded. Each participant signed an Institutional Review Board-approved protocol-specific
informed consent in accordance with federal and institutional guidelines.
Induction and Postremission Therapy
The details of the CALGB 19808 study have been described previously.12 Briefly, induction
chemotherapy consisted of daunorubicin, etoposide, and cytarabine, with or without
valspodar (PSC-833), an inhibitor of p-glycoprotein. The first 302 patients were randomized
to treatment with or without valspodar.
Postremission therapy depended on cytogenetic risk. Patients with core-binding factor AML
(ie, those patients with t(8;21)(q22;q22), inv(16)(p13q22), or t(16;16)(p13;q22)) received 3
courses of HiDAC.13
Those patients with non–core-binding factor AML in CR received HiDAC with high-dose
infusional etoposide followed by AHSCT as previously described.14,15 If unable to undergo
transplantation, patients received an alternative consolidation sequence consisting of HiDAC
with high-dose infusional etoposide followed by 2 courses of HiDAC.16
rIL-2 Treatment Plan
The doses and schedule of rIL-2 were developed in the prior phase 1/2 CALGB 9621 study.8
Patients were randomized between rIL-2 and observation after recovery from postremission
chemotherapy or AHSCT. A maximum of 120 days was permitted from day 1 of the final
course of consolidation chemotherapy or day 0 of AHSCT. The absolute neutrophil count
had to be >0.75 × 109/L and the platelet count >10 × 109/L without transfusions. A bone
marrow biopsy documenting a leukemia-free state with trilineage hematopoiesis was
required. Consent for the immunotherapy randomization was obtained at the time of
protocol registration, before induction therapy.
The 90 days of treatment with rIL-2 consisted of 6 courses of 10 to 16 days of low-dose
rIL-2 (1 × 106 U/m2 subcutaneously [SC] daily) interspersed with five 3-day high-dose
courses (12 × 106 U/m2−15 × 106 U/m2 SC daily) (Fig. 1). The last low-dose sequence
extended to 16 days to provide a total of 90 days of therapy. Low-dose rIL-2 therapy was to
be continued, with transfusion support as needed to maintain a platelet count >10 × 109/L. If
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the absolute neutrophil count was <0.5 × 109/L, therapy was held until recovery to >0.75 ×
109/L, at which time rIL-2 could be restarted with a 20% dose reduction. If transfusion
requirements increased, or if incapacitating fatigue developed or any nonhematologic
toxicity of >grade 2 other than fever, a 3-day to 7- day therapy interruption was prescribed,
followed by up to 3 dose reductions to 0.8 × 106 U/m2, 0.6 × 106 U/m2, or 0.4 × 106 U/m2.
Patients without a >grade 2 toxicity other than fever after the first 3-day high-dose sequence
were to have their dose of rIL-2 increased from 12 × 106 U/m2 to 15 × 106 U/m2 daily
starting with the second high-dose sequence. Patients experiencing >grade 2 nonhematologic
toxicity after high-dose rIL-2 underwent dose interruptions of 3 to 7 days, after which the
previously tolerated low dose of rIL-2 was given until the next high-dose cycle. Up to 3
reductions of 3 × 106 U/m2 each were allowed for patients who had been escalated to 15 ×
106 U/m2 and 2 reductions were permitted for patients who were not escalated above 12 ×
106 U/m2. Missed high-dose treatments were not made up.
Criteria for Response and Toxicity
National Cancer Institute Workshop criteria were used to define CR.17 The National Cancer
Institute Common Toxicity Criteria were used to grade toxicity.
Quality Control, Quality Assurance, and Auditing
Institutional Review Board approval was required for every participating institution with
written informed consent obtained from each patient. Patient registration, data collection,
and all statistical analyses were performed by the Alliance for Clinical Trials in Oncology
Statistics and Data Management Center. The medical records of 83 patients (39% of the 214
randomized patients) were audited; records from each participating institution were
reviewed. In addition, this study was monitored by the CALGB (Alliance) Data and Safety
Monitoring Committee following standard National Cancer Institute policies.
Statistical Analysis
Randomization on the current study used a randomized permuted block design with a block
size of 8 and a 1:1 allocation to the 2 treatments (rIL-2 or observation) with stratification by
the assigned induction regimen (cytarabine, daunorubicin, and etoposide [ADE] and
cytarabine, daunorubicin, etoposide, and valspodar [ADEP]) and cytogenetic risk group
(favorable or others). The randomization process was set up and maintained by the CALGB
(Alliance) Statistics and Data Management Center.
The primary endpoint was DFS from the date of the immunotherapy randomization. The
design assumed that 240 patients would achieve CR, complete all other treatment, and be
randomized between rIL-2 and observation. These patients would be followed until a total of
192 failures were observed, providing 90% power to detect a hazards ratio (HR) <0.625 with
respect to DFS. Analyses of DFS and overall survival (OS) used 2-sided log-rank tests18 at
the .05 significance level as well as proportional hazards regression models.19 For the
analysis of DFS, patients who were alive and in CR were censored at the time of last follow-
up. OS was measured from the date of the immunotherapy randomization until the date of
death; patients alive at the time of last follow-up were censored. Protocol-specified interim
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analyses were performed every 6 months after 100 patients were entered as previously
described.20
The primary analyses compared the outcomes of patients randomized to the rIL-2 treatment
arm with those who were randomized to the observation arm. Secondary analyses compared
outcomes for patients who did not receive any rIL-2 with those who received at least 1 dose
of rIL-2. In addition, a landmark analysis21 was conducted to compare outcomes by the
amount of rIL-2 received by day 120 after randomization. In these analyses, survival
duration was defined as the time from the landmark of 120 days to the event.
Survival estimates were calculated using the Kaplan-Meier method,22 and treatment groups
were compared using a 2-sided log-rank test at a significance level of .05. Univariable Cox
proportional hazards models were performed for both DFS and OS and the estimated HRs
and corresponding 95% confidence intervals (95% CIs) were calculated to compare
treatment groups within various subgroups defined by clinical parameters. Forest plots23
were generated to summarize these results and to evaluate any treatment covariate or
subgroup effect.
RESULTS
Between November 15, 2000 and March 31, 2006, 734 patients were registered. A CR was
achieved by 549 of the 716 evaluable patients (77%). After the completion of all
chemotherapy, 214 patients agreed to be randomized between rIL-2 therapy and observation.
Table 1 describes the well-balanced demographic and clinical characteristics of the
randomization arms.
Of 549 patients who achieved a CR, 63 (11%) were removed from protocol therapy to
receive allogeneic transplantation. Eighty-two patients (15%) refused randomization and 73
patients (13%) developed disease recurrence before randomization (Fig. 2) (Table 2).
Among the 107 patients assigned to receive rIL-2, 31 patients (29%) did not begin
treatment, almost all (25 patients) because of patient refusal. Another 30 patients (28%)
initiated treatment but failed to complete their 90-day course. Reasons for discontinuing
therapy included 19 patient refusals (18%) with grade 1 or grade 2 toxicity, and 5 patient
refusals (5%) with grade 3 or grade 4 toxicity; 6 patients (6%) developed disease recurrence
while receiving rIL-2. Seventy-six of the 107 patients assigned to receive rIL-2 therapy
(71%) received at least 1 dose of rIL-2; 46 patients (43%) received at least 50% of the
planned therapy and 25 patients (23%) received at least 90% of the planned therapy.
Toxicity
Severe adverse events were uncommon. Grade 3 and 4 toxicities were observed in at least
5% of patients and are shown in Table 2. Thrombocytopenia, neutropenia, fatigue, and
hypotension were the most common grade 3 and 4 events and were readily reversible.
Outcomes
By the protocol-specified intention-to-treat analysis, the HR for DFS was 0.75 (95% CI,
0.52–1.09; P =.13); the 5-year DFS rate was 42% for the observation arm and 53% for the
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rIL-2 treatment arm. Details are given in Figure 3. The HR for OS was 0.88 (95% CI, 0.54–
1.23; P =.34); the 5-year OS rate was 58% for the observation arm and 63% for the rIL-2
treatment arm. In an exploratory “as-treated” analysis in which patients who were
randomized to receive rIL-2 therapy but who either did not receive or refused their assigned
treatment were combined with the 107 patients in the observation arm, outcomes among the
76 patients who received at least 1 dose of rIL-2 were compared with the 138 patients who
did not receive any immunotherapy. The 5-year DFS rate was 43% in the no immunotherapy
group (median, 1.7 years) and 55% in the group treated with rIL-2 (median DFS not
reached; P =.11) (Fig. 4), whereas the 5-year OS rates were 60% in the observation group
and 61% in the group treated with rIL-2; neither group had reached the median OS at the
time of last follow-up. An additional exploratory landmark analysis comparing outcomes by
amount of rIL-2 received by day 120 after randomization (≥ 50% of the planned dose vs
<50% or no rIL-2 received) demonstrated similar trends with respect to DFS (P =.15 in both
instances) (Fig. 5) and no difference with respect to OS (P =.5). Univariable analyses for
DFS and OS using 9 variables demonstrated that only the European LeukemiaNet genetic
grouping24 significantly affected DFS and OS, whereas the baseline lactate dehydrogenase
level was found to be significantly associated with OS (data not shown). A forest plot
analysis showed HRs favoring rIL-2 with respect to DFS among all 16 variables studied
(Fig. 6) and OS in 13 of the 16 variables studied (data not shown), but the 95% CI crossed
unity in each instance.
DISCUSSION
Multiple studies of rIL-2 in patients with AML in first CR have failed to demonstrate
benefit. This has been summarized in a meta-analysis of 6 phase 3 randomized trials,
including preliminary data from the current report.5 Five of the 6 cited trials were published
between 2007 and 2010, well after the start of this study. One phase 3 trial that combined
rIL-2 with histamine dihydrochloride in patients with AML in CR favored the rIL-2 arm.25
The CALGB has completed 2 phase 3 trials in older and younger patients with AML in first
CR that evaluated the effect of the SC administration of rIL-2 on DFS. CALGB 9720, which
was performed in patients aged ≥60 years, demonstrated no benefit for treatment with
rIL-2.7 Our results in CALGB 19808 among patients aged <60 years did not reach statistical
significance with respect to DFS and OS.
This randomized immunotherapy maintenance trial encountered constraints with respect to
patient acceptance. Despite a lack of excessive toxicity, many patients declined to receive
their assigned immunotherapy either after randomization or after experiencing modest
toxicity. In our previous study of patients aged ≥60 years (CALGB 9720), among 320
patients in CR, 163 (51%) were randomized between rIL-2 and observation,7 a percentage
that is similar to that in the current study, taking into account that 11% of patients in
CALGB 19808 received allografts at the time of first CR. Consequently, 44% of
nonallografted patients in CR were randomized. After randomization, 22 of the 81 older
patients (27%) refused to begin or continue rIL-2 therapy, compared with 49 of the 107
younger patients (46%). In a subsequent study, CALGB 10503, patients aged <60 years with
AML received similar induction and consolidation therapy as in the current study. Of 349
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patients in first CR, 34% received a planned phase 2 decitabine maintenance sequence after
completing all postremission therapy.26 In both trials, the investigational therapy was given
after a prolonged course of intensive chemotherapy including AHSCT or multiple cycles of
HiDAC. We speculate that “treatment fatigue” may be a reason contributing to the refusal of
younger patients (15% in the current study and 9% in CALGB 10503) to receive additional
outpatient treatment after intensive postremission therapy.26 Withdrawal from therapy in the
absence of quantifiable toxicity may be an important obstacle to drug development.
Consideration should be given to establishing feasibility measurements alongside toxicity
scales as new therapies are evaluated.
NK cells are a central component of the innate immune response.
CD56brightCD16dim/negative NK cells expand at the time of interaction between low-dose
rIL-2 and its high-affinity receptor. Short courses of rIL-2 at higher doses can activate
cytotoxicity against NK cell-resistant tumor targets.20 These effects have been described in
vitro using concentrations of rIL-2 readily achieved with SC dosing,27 as well as in patients
with immunodeficiencies and malignancies.9,28 Significant expansion of NK cells with
cytolytic activity against autologous blasts was observed in a trial of continuous intravenous
infusion low-dose rIL-2 after HiDAC consolidation in younger patients with AML in first
CR.29
The NK cell population that is expanded by low-dose rIL-2 expresses fewer inhibitory killer
immunoglobulin receptors than CD56dim NK cells, whose cytotoxicity is inhibited by the
major histocompatibility complex class I ligands present on target cells.30 Conversely, rIL-2
also activates regulatory T cells (Tregs), which can dampen the autologous antitumor
immune response.31
The failure to reach statistical significance for DFS, the primary endpoint, is consistent with
the results of other studies of IL-2 as reported in the recently published meta-analysis.5
Unfortunately, in the current study, the number of patients randomized was far fewer than
anticipated, with a resultant decrease in power. The observed number of events was only
60% of the planned number. Thus, the power of this trial to detect the originally specified
HR was only 0.71, rather than the planned 0.90. Because of this, the results reported herein
are inconclusive with respect to the original design objective. The observed HR with the
originally planned 192 events would have reached a significance level of .05 (95% CI, 0.57–
0.99). There can be no way of knowing whether the observed HR would have been
maintained over the additional events.
We conclude that immunotherapy for patients with AML in first CR using this dose and
schedule of rIL-2 was not well accepted by patients after prolonged and intensive
consolidation therapies, including AHSCT. However, the observed results provide important
information regarding the use of rIL-2 in this setting. Patient refusal compromised the
original trial design despite an acceptable level of toxicity associated with rIL-2 therapy.
Significant improvements in outcomes were not observed. We believe that the unanticipated
failure to meet the accrual goals to this final part of the overall study with the consequent
loss of statistical power impacted on the outcomes of this trial. The goal of modulating the
innate immune response against minimal residual disease in patients with AML remains
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valid in our view. Trial designs have to anticipate the potential problem of therapy-related
fatigue by focusing on a patient’s antecedent intensity and length of therapy; the dislocations
and inconveniences related to late investigational interventions; and, not least, the need to
maintain physician commitment and enthusiasm throughout the process.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Treatment plan for recombinant interleukin-2 (rIL-2) maintenance therapy is shown. Low-
dose rIL-2 was given subcutaneously (SC) for 10 to 16 days. Each low-dose sequence was
followed by 3 days of high-dose rIL-2 administered SC. The course was completed with 16
days of low-dose rIL-2 therapy without further administration of high-dose rIL-2. Patients
were given a rest day after each high-dose sequence.
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A CONSORT (Consolidated Standards Of Reporting Trials) flow diagram demonstrating
the progress of patients in complete remission (CR) up to the point of randomization
between recombinant interleukin-2 (rIL-2) and observation is shown. “Received
consolidation” includes only those patients who received protocol-specified therapy. Sixty-
one of 549 patients in CR (11%) received allogeneic transplants. “Alternative” refers to the
therapy given to patients without core-binding factor acute myeloid leukemia who did not
receive autologous or allogeneic transplants. ADE indicates cytarabine, daunorubicin, and
etoposide; ADEP, cytarabine, daunorubicin, etoposide, and valspodar (PSC-833); allo
HSCT, allogeneic hematopoietic stem cell transplantation; HiDAC, high-dose cytarabine;
BMT, bone marrow transplantation.
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Disease-free survival among the 214 patients in complete remission randomized between
treatment with recombinant interleukin-2 (rIL-2) and observation is shown by intent-to-treat
analysis. CALGB indicates Cancer and Leukemia Group B.
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Exploratory analysis of disease-free survival according to whether any recombinant
interleukin-2 (rIL-2) treatment was received after the completion of postremission
chemotherapy is shown. CALGB indicates Cancer and Leukemia Group B; NA, median not
reached.
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Disease-free survival is shown using a landmark analysis comparing outcomes by amount of
recombinant interleukin-2 (rIL-2) received by day 120 after randomization (≥ 50% of the
planned dose vs <50% or no rIL-2 received). NA indicates median not reached.
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Forest plot analysis of disease-free survival is shown. Points to the left of the ordinate favor
treatment with recombinant interleukin-2 (rIL-2) whereas those to the right favor no therapy
(observation [obs]). 95% CI indicates 95% confidence interval; PS, performance status;
ADE, cytarabine, daunorubicin, and etoposide; ADEP, cytarabine, daunorubicin, etoposide,
and valspodar (PSC-833); ELN, European LeukemiaNet genetic grouping.
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TABLE 1
Immunotherapy Randomization
No. of registered patients 734
No. evaluable for response to induction therapy 716
No. with CR 549 (77%)
No.(% of CR)
Refused randomization 82 (15%)
Refused postremission therapy 15 (3%)
Developed disease recurrence before immunotherapy randomization 73 (13%)
Death after CR, before or after consolidation therapy 20 (4%)
Allogeneic HSCT in first CR 63 (11%)
Unresolved toxicity 45 (8%)
Failure to recovery blood counts by day 120 after AHSCT or last HiDAC 21 (4%)
Other/unknown 16 (3%)
Randomized to rIL-2 107 (19%)
Randomized to observation 107 (19%)
Abbreviations: AHSCT, autologous hematopoietic stem cell transplantation; CR complete remission; HiDAC, high-dose cytarabine; HSCT,
hematopoietic stem cell transplantation; rIL-2, recombinant interleukin-2.
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TABLE 2
Grade 3 and 4 Toxicities Observed in at Least 5% of Patients Treated With rIL-2a
Toxicity Grade 3 No. Grade 4 No.
Anemia 5 (7%) 0
Neutropenia 6 (8%) 9 (12%)
Thrombocytopenia 12 (16%) 6 (8%)
Hypotension 10 (13%) 1 (1%)
Fatigue 9 (12%) 0
Febrile neutropenia 4 (5%) 1 (1%)
Infection without neutropenia 4 (5%) 0
Dyspnea 4 (5%) 0
Abbreviation: rIL-2, recombinant interleukin-2.
a
The National Cancer Institute Common Toxicity Criteria were used to grade toxicity.
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